tirzepatide obstructive sleep apnea fda approval 2024 Huge news: has approved Zepbound (tirzepatide- GLP-1/GIP receptor agonist) for the treatment of moderate to severe in adults with obesity. As a cardiologist, this is a huge deal FDA approves weight-loss drug Zepbound

While Semaglutide GLP-1 has proven successful, tirzepatide has shown even better results in clinical trials

As of July 2025, these search trends mark a clear inflection point

Clinical data shows these symptoms happen because food takes too long to leave the stomach [10]

Mechanism of action: Tirzepatide is a long-acting dual GIP and GLP-1 receptor agonist

This dual mechanism distinguishes tirzepatide from single-receptor agonists in its class

This is why patients using oral Mounjaro alternatives often report: Weak appetite suppression No change in cravings Lack of fat-loss momentum Zero metabolic difference Side effects without results A sense of this isnt doing anything In other words, most oral tirzepatide pill forms are not effective